Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer’s disease: Findings from three well-characterized cohorts.

December 18, 2019

Authors: Amariglio RE, Buckley RF, Burnham S, Chhatwal J, Dobson A, Donohue MC, Dore V, Hanseeuw BJ, Hedden T, Jacobs HIL, Johnson KA, Kirn D, Lim YY, Maruff P, Masters CL, Mormino EC, Papp KV, Properzi MJ, Rabin JS, Rentz DM, Rowe CC, Schultz AP, Sperling RA, Villemagne VL, Waller M

Journal: Alzheimer's and Dementia

DOI: 10.1016/j.jalz.2018.04.010

Year Published: 2018

INTRODUCTION:
Our objective was to investigate the effect of sex on cognitive decline within the context of amyloid β (Aβ) burden and apolipoprotein E genotype.

METHODS:
We analyzed sex-specific effects on Aβ-positron emission tomography, apolipoprotein, and rates of change on the Preclinical Alzheimer Cognitive Composite-5 across three cohorts, such as the Alzheimer’s Disease Neuroimaging Initiative, Australian Imaging, Biomarker and Lifestyle, and Harvard Aging Brain Study (n = 755; clinical dementia rating = 0; age (standard deviation) = 73.6 (6.5); female = 55%). Mixed-effects models of cognitive change by sex, Aβ-positron emission tomography, and apolipoprotein ε4 were examined with quadratic time effects over a median of 4 years of follow-up.

RESULTS:
Apolipoprotein ε4 prevalence and Aβ burden did not differ by sex. Sex did not directly influence cognitive decline. Females with higher Aβ exhibited faster decline than males. Post hoc contrasts suggested that females who were Aβ and apolipoprotein ε4 positive declined faster than their male counterparts.

DISCUSSION:
Although Aβ did not differ by sex, cognitive decline was greater in females with higher Aβ. Our findings suggest that sex may play a modifying role on risk of Alzheimer’s disease-related cognitive decline.

Back to Publications